BioMarin Pharmaceutical | BMRN - Pre Tax Profit


BioMarin Pharmaceutical reported $141.2M in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 46.47M 42.49M Jun/2026
Agios Pharmaceuticals USD -99.11M 9.94M Mar/2026
Alnylam Pharmaceuticals USD 177.81M 43.85M Jun/2026
Amgen USD 2.08B 570M Mar/2026
Bayer EUR 321M 2.67B Jun/2026
Biogen USD 647.3M 269.6M Jun/2026
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Gilead Sciences USD -7.53B 10.11B Jun/2026
Incyte USD 751.51M 407.91M Jun/2026
Insmed USD -11.37M 150.72M Jun/2026
Ionis Pharmaceuticals USD -114M 21M Jun/2026
Moderna USD -1.33B 535M Mar/2026
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
PTC Therapeutics USD -2.46M 136.62M Mar/2026
Puma Biotechnology USD 20.61M 24.76M Sep/2024
Regeneron Pharmaceuticals USD 1.53B 696.6M Jun/2026
Roche Holding CHF 11.17B 6.38B Jun/2026
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Sanofi EUR 2B 3.16B Mar/2026
Sarepta Therapeutics USD -1.75M 344.92M Jun/2026
Ultragenyx Pharmaceutical USD -91M 93M Jun/2026
United Therapeutics USD 372.7M 54.4M Jun/2026
Vertex Pharmaceuticals USD 1.39B 138.9M Jun/2026